Results 41 to 50 of about 34,167 (118)

Effect of glucagon-like peptide-1 receptor agonists on body weight and urinary albumin-to-creatinine ratio in patients with and without type 2 diabetes: A systematic review and meta-analysis

Journal of International Medical Research
Objective Glucagon-like peptide-1 receptor agonists are established for weight management and cardiovascular risk reduction, with emerging evidence for kidney protection.
Rong Huang, Bin Wang
doaj   +1 more source

Effect of Glucagon‐Like Peptide 1 Receptor Agonists on Patients With Rheumatoid Arthritis

ACR Open Rheumatology
Objective Glucagon‐like peptide 1 receptor agonists (GLP‐1RAs) are approved for weight loss, diabetes, and cardiovascular risk reduction. Despite widespread use, GLP‐1RAs have not been well studied in patients with rheumatoid arthritis (RA).
David A. Kellner, Elizabeth Dente, Vincent Tran, Travis Welsh, Victor Tran, Angshuman Saha, Joshua F. Baker, David A. Elashoff, Veena K. Ranganath   +8 more
doaj   +1 more source

Integrative gene-metabolite network analysis of GLP-1 receptor agonists and related incretin pathways in cardiometabolic health

npj Systems Biology and Applications
Glucagon-like peptide-1 (GLP-1) is a hormone known for its critical functions in managing blood sugar and offering cardiovascular benefits. Our study focuses on Glucagon Like Peptide 1 Receptor (GLP1R) agonists that act beyond glycemic control in ...
Zofia Wicik, Anna Nowak-Szwed, Ceren Eyileten, Harald Sourij, Dirk von Lewinski, Svjatoslavs Kistkins, Joanna Borkowska, Marek Postuła   +7 more
doaj   +1 more source

Survodutide - Novel Anti Obesity Drug

JK Science
Survodutide (BI 456906) is a novel, dual agonist of glucagon and glucagon-like peptide-1 (GLP-1) receptors developed as a once-weekly subcutaneous injection for the management of obesity.
Irtiqa Ayani Rathore, Sana Malik, Amarjeet Singh, Vishal R Tandon, Annil Mahajan   +4 more
doaj  

Semaglutide treatment for type 2 diabetes in a patient with chronic myeloid leukemia: A case report and review of the literature

Open Medicine
Comorbid type 2 diabetes mellitus (T2DM), severe obesity, and chronic myeloid leukemia (CML) present therapeutic challenges, especially given the limited data on glucagon-like peptide-1 (GLP-1) receptor agonists in this setting.
Zhang Yuchen, Li Anxin
doaj   +1 more source

Glucagon-like Peptide-1 Receptor Agonists and the Perioperative Patient. [PDF]

AORN J
Fischer L.
europepmc   +1 more source

Prescription Sequence Symmetry Analysis of Glucagon-Like Peptide-1 Receptor Agonists and Neuropsychiatric Conditions. [PDF]

Clin Pharmacol Ther
Alfonso Arvez MJ, Wade S, Goordeen D, Ilomäki J, Cross AJ, Langiu M, Tan GSQ.   +6 more
europepmc   +1 more source

GLP-1 agonists in the treatment of chronic kidney disease in type 2 diabetes and obesity

The Journal of Clinical Investigation
Glucagon-like peptide-1 (GLP-1) was initially considered to be a hormone with a predominant role in regulating glucose metabolism by inducing insulin secretion, reducing glucagon secretion, and ameliorating insulin resistance, with the last effect being ...
Mark E. Cooper, Daniël H. van Raalte
doaj   +1 more source

Therapeutic Potential of Glucagon-like Peptide-1 Receptor Agonists in Respiratory Disorders. [PDF]

Int J Mol Sci
Russjan E, Zając D, Kaczyńska K.
europepmc   +1 more source

Discontinuation of glucagon-like peptide-1 receptor agonists among US adults: A national survey. [PDF]

J Manag Care Spec Pharm
DiStefano MJ, Zon J, Olson EG, Levy JF, Anderson GF, Alexander GC.   +5 more
europepmc   +1 more source